<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413552</url>
  </required_header>
  <id_info>
    <org_study_id>INDV-2000-101</org_study_id>
    <nct_id>NCT04413552</nct_id>
  </id_info>
  <brief_title>INDV-2000 First in Human</brief_title>
  <official_title>A Phase I, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a single ascending dose (SAD) study conducted to identify the maximum
      tolerated dose (MTD). After completion of the SAD portion of the study and acceptable safety
      evaluation, a food-interaction, single-dose study under fed and fasted conditions will be
      conducted.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part I-sequential escalating doses will be administered Part II-study medication will be administered under fed and fasted conditions</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of single doses of INDV-2000 as determined by adverse event reporting</measure>
    <time_frame>Adverse events will be measured from time of informed consent to end of study participation for each cohort (up to 45 days)</time_frame>
    <description>Occurrence of any adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs) as measured by clinically significant changes in laboratory values</measure>
    <time_frame>Labs will be assessed from screening until the end of subject participation (end of study or early termination visit as applicable), up to 45 days from the screening visit.</time_frame>
    <description>Observed values and changes from baseline in clinical laboratory parameters will be summarized by analysis visit (frequency and percentages for each category). Clinically significant changes from baseline requiring additional assessment or treatment will be reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs as measured by changes in electrocardiogram (ECG) intervals</measure>
    <time_frame>Electrocardiographic assessments will be performed at screening, and intermittently until the end of subject participation (end of study or early termination visit as applicable), up to 45 days from the screening visit</time_frame>
    <description>Observed values and changes from baseline in ECG interval measurements will be summarized by analysis visit. Clinically significant changes from baseline will be reported as adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs as measured by changes from baseline in vital signs measures</measure>
    <time_frame>Vital signs will be assessed from screening, until the end of subject participation (end of study or early termination visit as applicable), up to 45 days from the screening visit.</time_frame>
    <description>Observed values and changes from baseline in vital signs (blood pressure, respiratory rate, heart rate and temperature) will be summarized by analysis visit. Clinically significant changes will be reported as adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TEAEs as measured by physical examination changes</measure>
    <time_frame>Labs will be assessed from screening, until the end of subject participation (end of study or early termination visit as applicable)</time_frame>
    <description>Clinically significant changes in physical examination findings will be reported as adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic (PK) parameters of single doses of INDV-2000 as measured by maximum concentration (Cmax)</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 72 hours post-dose</time_frame>
    <description>Concentrations for INDV-2000 and its metabolite (M12) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of single doses of INDV-2000 as measured by time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 72 hours post-dose</time_frame>
    <description>Concentrations for INDV-2000 and its metabolite (M12) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of single doses of INDV-2000 as measured by area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 72 hours post-dose</time_frame>
    <description>Concentrations for INDV-2000 and its metabolite (M12) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of single doses of INDV-2000 as measured by plasma clearance</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 72 hours post-dose</time_frame>
    <description>Concentrations for INDV-2000 and its metabolite (M12) will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of single doses of INDV-2000 as measured by plasma terminal half-life</measure>
    <time_frame>PK samples will be obtained at selected timepoints from pre-dose until 72 hours post-dose</time_frame>
    <description>Concentrations for INDV-2000 and its metabolite (M12) will be measured</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Part I-Active arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II-Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each cohort will be randomized to either placebo-matched or active INDV-2000 in increasing doses. In each cohort a sentinel group of 2 subjects will be randomized and dosed ahead of the rest of the cohort. A review of safety data will be completed prior to administration of doses to the remainder of the cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II-Active arm-fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medication will be administered after a high fat meal. Dose to be determine based on a well-tolerated dose studied in Part I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II-Active arm-fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medication will be administered under fasted conditions. Dose to be determine based on a well-tolerated dose studied in Part I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INDV-2000</intervention_name>
    <description>Study medication (active) will be administered as either powder in solution or powder in capsule, depending on dose administered.</description>
    <arm_group_label>Part I-Active arm</arm_group_label>
    <arm_group_label>Part II-Active arm-fasting</arm_group_label>
    <arm_group_label>Part II-Active arm-fed</arm_group_label>
    <other_name>C4X</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>Study medication (placebo) will be administered as either powder in solution or powder in capsule, depending on dose administered.</description>
    <arm_group_label>Part II-Placebo arm</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be able to verbalize understanding of the consent form, able to provide written
             informed consent, and verbalize willingness to complete study procedures, be able to
             comply with protocol requirements, rules and regulations of study site, and be likely
             to complete all the study interventions.

          -  Must be considered a healthy male or non-childbearing female for Part I

          -  For part II, must be a healthy male who did not participate in Part I who is willing
             to consume a high-fat meal.

          -  Body mass index (BMI) within 18.0 to 30.0 kg/m2, inclusive (minimum weight of at least
             50.0 kg at Screening)

          -  Male subjects who are sexually active with female partners of child-bearing potential
             must use, with their partner, a condom plus an approved method of effective
             contraception from time of screening until 90 days after last dose of Investigational
             Medicinal Product (IMP). Additionally, male subjects must agree to not donate sperm
             during the study and for at least 90 days from last dose of IMP.

        Exclusion Criteria:

          -  Have a medical history of clinically significant neurological, cardiovascular, renal,
             hepatic, chronic respiratory or gastrointestinal disease, or psychiatric disorder as
             judged by an Investigator,

          -  Have clinically significant abnormal biochemistry, hematology or urinalysis results as
             judged by an Investigator,

          -  Have a history of narcolepsy or other significant sleep disorders

          -  Have disorders that may interfere with drug absorption, distribution, metabolism and
             excretion (ADME) processes,

          -  Positive test results for HIV-1/HIV-2 Antibodies, Hepatitis B surface Antigen (HBsAg)
             or Hepatitis C Antibody (HCVAb).

          -  Serious cardiac illness or other medical condition including, but not limited to:
             Uncontrolled arrhythmias; History of congestive heart failure (CHF); Myocardial
             infarction &lt;6 months from receipt of first dose of IMP; Uncontrolled symptomatic
             angina; Corrected QT value (QTcF) &gt;450 msec for males and &gt;470 msec for females or
             history of prolonged QT syndrome; Have a blood pressure reading outside of the
             following range: Systolic &lt;86 or &gt;149 mmHg; Diastolic &lt;50 or &gt;94 mmHg

          -  Current active hepatic or biliary disease. Subjects with Cholecystectomy &lt;90 days
             prior to screening.

          -  Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week
             (1 unit = Â½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).

          -  Positive test result for alcohol and/or drugs of abuse at screening or prior to the
             first IMP administration.

          -  Current smokers and those who have smoked within the last 90 days. Current users of
             e-cigarettes and nicotine replacement products, and those who have used these products
             within the last 90 days.

          -  Concurrent treatment or treatment with an investigational drug within 30 days prior to
             the first dose.

          -  Blood donation of approximately 500 mL within 56 days or plasma donation within 7 days
             of screening.

          -  Subjects who are taking, or have taken, any prescribed or over-the-counter drugs
             (other than 2 g per day acetaminophen, hormone replacement therapy, hormonal
             contraception) or herbal remedies in the 14 days before IMP administration. Exceptions
             may apply on a case by case basis if considered not to interfere with the objectives
             of the study, as agreed by an Investigator and Sponsor's Medical Monitor.

          -  Any consumption of food or drink containing poppy seeds, grapefruit or Seville oranges
             within 7 days prior to the IMP administration

          -  Treatment with any known drugs that are moderate or strong inhibitors/inducers of
             cytochrome P450 (CYP) 3A4 within 30 days prior to first dose of IMP.

          -  Known allergy or hypersensitivity to IMP or its excipients.

          -  Any condition that, in the opinion of an Investigator, would interfere with evaluation
             of the IMP or interpretation of subject safety or study results.

          -  Affiliated with, or a family member of, site staff directly involved in the study, or
             anyone with a financial interest in the outcome of the study.

          -  Subjects who are unable, in the opinion of an Investigator, to comply fully with the
             study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Kankam</last_name>
    <role>Principal Investigator</role>
    <affiliation>altasciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Dobbins</last_name>
    <phone>804 379-1090</phone>
    <email>robert.dobbins@indivior.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunita Shinde</last_name>
    <phone>804 379-1090</phone>
    <email>sunita.shinde@indivior.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Reiber</last_name>
      <email>sreiber@altasciences.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

